Description
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Location: CPMC (San Francisco)
Please contact: clinicalresearch@sutterhealth.org about study Advanced CIDP 1
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Recruitment Status
Active, Recruiting
Start Date
August 18, 2020
Related Studies
GXCA
Investigator: Lawrence Dickinson, M.D
Genetics and Comorbidity of Migraine
Investigator: Alice R. Pressman, Ph.D., M.S.
Mindfulness and Migraine: A Randomized Controlled Trial
Investigators: Alice R. Pressman, Ph.D., M.S., Sylvia Sudat, PhD
Using Electronic Health Records to Identify Gaps in Migraine Headache Care: A Step Towards Improving Patient Outcomes
Investigator: Alice R. Pressman, Ph.D., M.S.